way 100135 has been researched along with flumazenil in 1 studies
| Studies (way 100135) | Trials (way 100135) | Recent Studies (post-2010) (way 100135) | Studies (flumazenil) | Trials (flumazenil) | Recent Studies (post-2010) (flumazenil) |
|---|---|---|---|---|---|
| 143 | 0 | 34 | 4,673 | 426 | 981 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furuyashiki, T; Miyamoto, C; Narumiya, S; Ohinata, K; Suzuki, C | 1 |
1 other study(ies) available for way 100135 and flumazenil
| Article | Year |
|---|---|
Central PGE2 exhibits anxiolytic-like activity via EP1 and EP4 receptors in a manner dependent on serotonin 5-HT1A, dopamine D1 and GABAA receptors.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Benzazepines; Bicuculline; Brain; Dinoprostone; Flumazenil; GABA Modulators; GABA-A Receptor Antagonists; Male; Mice; Mice, Knockout; Neuropsychological Tests; Piperazines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Receptors, GABA-A; Receptors, Prostaglandin E, EP1 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Serotonin Antagonists | 2011 |